Cofoe Medical Technology Co., Ltd.
可孚醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1187)

ANNOUNCEMENT
2026 INTERIM PROFIT DISTRIBUTION PLAN

Important Notice:

- The 2026 interim profit distribution plan of Cofoe Medical Technology Co., Ltd. (the "**Company**"): to distribute cash dividends of RMB6 (tax inclusive) for every 10 shares held by all the shareholders, based on the total number of shares as at the record date fixed for the implementation of the 2026 interim profit distribution after deduction of the number of shares in the Company's special securities accounts designated for repurchase. No conversion of capital reserve fund into share capital or bonus issue will be made.

- In case of any change in the share capital of the Company from the date on which the profit distribution plan is announced to the record date fixed for the implementation of the profit distribution, adjustments will be made to the total cash payouts based on the total number of shares eligible for distribution as at the record date while maintaining the cash payout ratio unchanged.

I. CONSIDERATION PROCEDURES

At the 8th meeting of the third session of the board of directors of the Company held on August 28, 2026, the Resolution on the 2026 Interim Profit Distribution Plan was considered and approved, which is subject to consideration at the general meeting of the Company.

II. BASIC INFORMATION OF THE PROFIT DISTRIBUTION PLAN

1. The profit distribution plan proposed is for the interim period of 2026.

2. Based on the Company's 2026 interim financial statements (unaudited), the Company recorded net profit attributable to shareholders of the listed company of RMB202.26 million for the first half of 2026, while the net profit of the parent company for the same period amounted to RMB97.17 million. As at June 30, 2026, the cumulative undistributed profits contained in the Company's consolidated financial statements amounted to RMB716.27 million, while the cumulative undistributed profits of the parent company were RMB230.61 million. In accordance with the principle that the amount available for distribution shall be subject to the lower of the profits as contained in the consolidated financial statements and the financial statements of the parent company, the Company's profits available for distribution for the first half of 2026 amounted to RMB230.61 million. The Company has made provision for the statutory surplus reserve fund in accordance with the Company Law of the People's Republic of China (《中華人民共和國公司法》) and the provisions of the Articles of Association of the Company.

3. The 2026 interim profit distribution plan is as follows: the Company proposes to distribute cash dividends of RMB6 (tax inclusive) for every 10 shares held by all the shareholders based on the total number of shares as at the record date fixed for the implementation of the 2026 interim dividend distribution after deduction of the number of shares in the Company's special securities accounts designated for repurchase. No conversion of capital reserve fund into share capital or bonus issue will be made. Calculated preliminarily based on the total number of shares of 227,129,319, which is arrived at after deducting the 8,767,681 repurchased shares in the Company's special securities accounts designated for repurchase from the total number of shares of 235,897,000 as at August 28, 2026, the record date, it is estimated that the interim cash dividend payouts amount to RMB136.28 million (tax inclusive).

In case of any change in the share capital of the Company from the date on which the profit distribution plan is announced to the record date fixed for the implementation of the profit distribution, adjustments will be made to the total cash payouts based on the total number of shares eligible for distribution as at the record date while maintaining the cash payout ratio unchanged.

The cash dividends, as denominated and declared in Renminbi, will be paid in Renminbi for A shares and in Hong Kong dollars for H shares. The foreign exchange rate of Hong Kong dollars against Renminbi will be subject to the average central parity rate quoted by the People's Bank of China for the five business days preceding the date on which the profit distribution plan is resolved at the general meeting of the Company.

III. RATIONALITY OF THE CASH DISTRIBUTION PLAN

The profit distribution plan has been proposed by the board of directors of the Company taking into comprehensive consideration the profitability, financial condition and future development prospects, among other factors, of the Company, which is in line with the relevant requirements of the Company Law of the People's Republic of China (《中華人民共和國公司法》), Regulatory Guidelines for Listed Companies No. 3 – Cash Dividends by Listed Companies (《上市公司監管指引第3號－上市公司現金分紅》) and other laws, regulations and regulatory documents, as well as the Articles of Association of the Company, and will enable all shareholders to share in the growth and operating results of the Company. As implementation of the profit distribution plan will not cause any liquidity strain or other adverse impact on the Company, it is therefore reasonable.

IV. MISCELLANEOUS

Prior to the publication of the profit distribution plan, the Company strictly managed the scope of insiders and duly fulfilled its notification obligations to the relevant insiders regarding their confidentiality obligations and the prohibition on insider trading.

The profit distribution plan is subject to consideration and approval at the 2026 third extraordinary general meeting of the Company. Investors are advised to be aware of the investment risks involved.

This announcement is published in both Chinese and English, and in case of any inconsistencies, the Chinese version shall prevail.

The board of directors of the Company would like to remind investors and shareholders of the Company to exercise caution while dealing in the securities of the Company.

By Order of the Board
Cofoe Medical Technology Co., Ltd.
ZHANG Min
Executive Director and Chairman of the Board

Hong Kong, August 28, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive directors.